- Field Trip Health (FTRP) will begin trading on the NASDAQ on July 29 under the symbol FTRP
- The company’s common shares will continue trading on the TSX but will be delisted from the OTCQX
- The company’s shares are eligible for electronic clearing and settlement through the Depository Trust Company
- Ronan Levy and Ellen Lubman will join the compensation committee and Mujeeb Jafferi and Dr. Ryan Yermus will resign as directors
- Mr. Jafferi and Dr. Yermus will continue to serve as Field Trip’s Chief Operating Officer and Chief Clinical Officer
- Field Trip Health is a global leader in the development and delivery of psychedelic therapies
- Field Trip Health Ltd. (FTRP) is down 0.40 per cent, trading at C$7.39 per share at 4 pm ET
Field Trip Health (FTRP) will begin trading on the NASDAQ on July 29 under the symbol FTRP.
Hannan Fleiman, Field Trip’s President remarked,
“Listing on the Nasdaq Global Select Market, NASDAQ’s top tier, is a mark of achievement and stature for listed companies who must meet the highest the highest financial and liquidity qualifications for inclusion. We are proud of the rapid progress we have made in a relatively short period of time and this accomplishment is a testament to the efforts of our employees and partners. We look forward to building value for our shareholders as we enter the next stage of our growth.”
Dr. Ryan Yermus, Field Trip’s Chief Clinical Officer, added,
“Listing on the leading securities exchange for biotech companies will enable more investors both in the U.S. and globally to support Field Trip as we advance our ground-breaking work in the psychedelics industry. We continue to make steady progress with the development of FT-104, a novel psychedelic molecule, with GMP production underway in preparation for Phase 1 studies, and other strategic initiatives which will further strengthen our leadership position in the industry.”
The company’s common shares will continue trading on the TSX under its current symbol FTRP. Field Trip’s shares will cease to be quoted on the OTCQX.
The company’s shares are eligible for electronic clearing and settlement through the Depository Trust Company (DTC).
Ronan Levy and Ellen Lubman will join the compensation committee and Mujeeb Jafferi and Dr. Ryan Yermus will resign as directors. Mr. Jafferi and Dr. Yermus will continue to serve as Field Trip’s Chief Operating Officer and Chief Clinical Officer, respectively.
Field Trip Health is a global leader in the development and delivery of psychedelic therapies.
Field Trip Health Ltd. (FTRP) is down 0.40 per cent, trading at C$7.39 per share at 4 pm ET.
